Invited review: palmitic and stearic acid metabolism in lactating dairy cows.

Energy is the most limiting nutritional component in diets for high-producing dairy cows. Palmitic (C16:0) and stearic (C18:0) acids have unique and specific functions in lactating dairy cows beyond a ubiquitous energy source. This review delineates their metabolism and usage in lactating dairy cows from diet to milk production. Palmitic acid is the fatty acid (FA) found in the greatest quantity in milk fat. Dietary sources of C16:0 generally increase milk fat yield and are used as an energy source for milk production and replenishing body weight loss during periods of negative energy balance. Stearic acid is the most abundant FA available to the dairy cow and is used to a greater extent for milk production and energy balance than C16:0. However, C18:0 is also intimately involved in milk fat production. Quantifying the transfer of each FA from diet into milk fat is complicated by de novo synthesis of C16:0 and desaturation of C18:0 to oleic acid in the mammary gland. In addition, incorporation of both FA into milk fat appears to be limited by the cow's requirement to maintain fluidity of milk, which requires a balance between saturated and unsaturated FA. Oleic acid is the second most abundant FA in milk fat and likely the main unsaturated FA involved in regulating fluidity of milk. Because the mammary gland can desaturate C18:0 to oleic acid, C18:0 appears to have a more prominent role in milk production than C16:0. To understand metabolism and utilization of these FA in lactating dairy cows, we reviewed production and milk fat synthesis studies. Additional and longer lactation studies on feeding both FA to lactating dairy cows are required to better delineate their roles in optimizing milk production and milk FA composition and yield.

Effects of calcium salts of long-chain fatty acids added to a diet containing choice white grease on lactation performance.

We studied the effect of increased energy density of diets during early lactation on lactational performance of cows injected with bST. Total mixed rations contained 50% forage (DM) and 2.5% choice white grease during the first 14 wk of lactation. Thirty cows were fed diets with grease as the only supplemental fat, and 15 cows were fed grease plus 1.8% calcium salts of long-chain fatty acids. One-half of the cows fed grease and all cows fed grease plus calcium salts of long-chain fatty acids received 640 mg/28 d of sustained-release bST from 6 to 44 wk postpartum. Calcium salts of long-chain fatty acids did not increase milk yield, 3.5% FCM, or DMI during the first 14 wk postpartum or during 15 to 44 wk postpartum. Administration of bST increased milk fat concentration .4% units during the first 14 wk postpartum. Cows receiving bST had higher DMI and produced 18.5% more 3.5% FCM from 15 to 44 wk postpartum than did controls. Calcium salts of long-chain fatty acids or bST injections did not influence body condition score or BW. These data suggest that cows yielding 30 to 35 kg of milk/d during the first 14 wk of lactation may not respond to added fat over 2.5%.

Effects of recombinant bovine somatotropin on milk production, body composition, and physiological parameters.

Twenty-eight multiparous Holstein cows were utilized to determine effects of long-term administration of recombinant bovine somatotropin on lactational performance, body condition, body composition, hormones, blood constituents, and physiological parameters. Treatments were 0 (control), 10.3, 20.6, and 41.2 mg recombinant bovine somatotropin administered daily as subcutaneous injections beginning 4 to 5 wk postpartum and continuing for 38 wk. A total mixed diet of 28% corn silage, 22% alfalfa hay cubes, and 50% corn-soybean meal-based grain mixture was fed. Fat-corrected milk yields were increased 12 to 25% for cows treated with somatotropin as compared with controls (29.9 kg/d). Milk composition was similar among treatments. Cows receiving somatotropin consumed 4 to 10% more feed and were 11 to 17% more efficient than controls for conversion of feed to milk. Body weight changes were not significantly different among treatments, but cows receiving somatotropin gained 4 to 10% less weight than controls. Body fat (kg) of cows receiving 20.6 and 41.2 mg/d was less than that of cows receiving 10.3 mg/d or no somatotropin. Estimated weights of body protein and mineral, most blood constituents, respiratory rates, and body temperature were not affected by somatotropin administration. Plasma fatty acids were elevated and hematocrit values were reduced. Plasma insulin, serum somatotropin, and heart rate increased concurrently with somatotropin administration.

Somatotropin treatment for a second consecutive lactation.

Twenty-five Holstein cows were used to examine effects of recombinant bST administration for a second successive lactation on milk yield and composition, BW change, body condition, and health. Treatments were 0 (physiological saline), 10.3, 20.6, and 33 mg bST/d (8, 8, 7, and 3 cows per treatment, respectively). Saline and bST were given daily as subcutaneous injections beginning 4 to 5 wk postpartum and continuing for 38 wk. Somatotropin increased 3.5% FCM yield linearly from 8 to 36% over controls (control FCM was 30.1 kg/d). Milk composition was not affected by bST except that milk from cows given the 10.3-mg dosage had slightly higher Ca and P contents than did milk from cows receiving 0 or 20.6 mg. Cows receiving bST were 9 to 30% more efficient than controls in converting feed to milk. Body weight gain was unaffected by treatment. Average condition score was unchanged for control cows during the first 84 d following initiation of treatment, but declined in cows given bST. Thereafter, condition score increased in a similar manner for all groups. No treatment-related patterns were found in incidence of mastitis, feet and leg problems, ketosis, or milk fever. Blood hormone, chemistry, and hematology revealed no effects of bST treatment other than to raise plasma bST concentrations. Under conditions of this experiment, use of bST during a second consecutive lactation did not change the normal physiology or productive capacity of lactating cows.

Responses of dairy cows supplemented with somatotropin during weeks 5 through 43 of lactation.

Beginning at wk 5 of lactation, 136 cows (34 per treatment) were supplemented daily for 38 wk with 0, 10.3, 20.6, or 41.2 mg of recombinantly derived bST monomer. Cows were obtained from University of Kentucky, University of Minnesota, University of Pennsylvania, and The Ohio State University. Nine cows (4 at 0 mg/d, 1 at 10.3 mg/d, 1 at 20.6 mg/d, and 3 at 41.2 mg/d) did not complete the experiment because of health problems. Data from these cows were included in the reproduction and health databases but not in the production database. Cows supplemented with bST produced more milk, consumed more feed, had lower rates of BW gain, and had improved efficiencies of milk production (conversion of feed and NEL to milk). Additional increases in productivity were modest at 20.6 and 41.2 mg/d versus productivity at 10.3 mg/d of bST. Concentrations of fat, protein, and TS in milk were unaffected. At 10.3 mg/d, bST did not adversely affect reproduction or health.